{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:38:12Z","timestamp":1790797092922,"version":"4.1.0"},"reference-count":20,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK inhibitors. Invasive fungal infections carry a high morbidity and mortality risk. There have been several case reports describing the association between aspergillosis and ibrutinib treatment, but none with acalabrutinib, to our knowledge. In this case report, we describe a patient with CLL who developed an intracranial Aspergillus fumigatus infection while receiving acalabrutinib.<\/jats:p>","DOI":"10.3390\/curroncol28010081","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T04:18:50Z","timestamp":1612844330000},"page":"837-841","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5299-4233","authenticated-orcid":false,"given":"Omar","family":"Alkharabsheh","sequence":"first","affiliation":[{"name":"Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhareth","family":"Alsayed","sequence":"additional","affiliation":[{"name":"Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Morlote","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00277-012-1460-z","article-title":"Immunological aspects in chronic lymphocytic leukemia (CLL) development","volume":"91","author":"Llorente","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mmcr.2019.12.007","article-title":"A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy","volume":"27","author":"Eichenberger","year":"2020","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1177\/1078155218788717","article-title":"Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook","volume":"25","author":"Faisal","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.medmal.2018.01.003","article-title":"Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?","volume":"48","author":"Gaye","year":"2018","journal-title":"Med. Mal. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2141.2010.08283.x","article-title":"Enemy of the (immunosuppressed) state: An update on the pathogenesis of Aspergillus fumigatus infection","volume":"150","author":"Lewis","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/IPC.0000000000000722","article-title":"Disseminated Cryptococcal Infection in a Patient Receiving Acalabrutinib for Chronic Lymphocytic Leukemia","volume":"27","author":"Wilson","year":"2019","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious complications of chronic lymphocytic leukemia","volume":"33","author":"Wadhwa","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2010-04-281170","article-title":"Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia","volume":"117","author":"Fiedler","year":"2011","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3389\/fimmu.2020.02158","article-title":"BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia","volume":"11","author":"Fiorcari","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1158\/0008-5472.CAN-15-1490","article-title":"Myeloid-Derived Suppressor Cells Express Bruton\u2019s Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment","volume":"76","author":"Stiff","year":"2016","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/591458","article-title":"Human platelets attenuate Aspergillus species via granule-dependent mechanisms","volume":"198","author":"Perkhofer","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QCO.0000000000000611","article-title":"Azole antifungals and new targeted therapies for hematological malignancy","volume":"32","author":"Lindsay","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e2018063","DOI":"10.4084\/mjhid.2018.063","article-title":"Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs","volume":"10","author":"Facchinelli","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/81\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:21:08Z","timestamp":1760160068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/1\/81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["curroncol28010081"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28010081","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]}}}